Is Silicon Valley ready for biotech???s newest unethical prodigies?

The future was looking unbelievably bright for Forbes 30-under-30 healthcare golden boy Gabriel Otte, CEO of liquid biopsy startup Freenome, the recipient of $65M in seed funding from Silicon Valley venture capital firm Andreessen Horowitz, also known as a16z. A Cornell graduate who worked at Apple at 17, Otte enrolled as a graduate student at the University of Pennsylvania in 2011, working in the lab of Dr. Shelley Berger within the Genomics and Computational Biology (GCB) program. Otte then left prematurely under somewhat murky circumstances — according to him, “[on leave because] starting a company violated my PhD contract” 

Read More